Structural basis for selectivity and diversity in angiotensin II receptors

Nature

Volumn 544, Issue 7650, 2017, Pages 327-332

  Zhang, Haitao ^a,b   Han, Gye Won ^a   Batyuk, Alexander ^c   Ishchenko, Andrii ^a   White, Kate L ^a   Patel, Nilkanth ^a   Sadybekov, Anastasiia ^a   Zamlynny, Beata ^d   Rudd, Michael T ^d   Hollenstein, Kaspar ^d   Tolstikova, Alexandra ^e,f   White, Thomas A ^e   Hunter, Mark S ^c   Weierstall, Uwe ^g   Liu, Wei ^g   Babaoglu, Kerim ^d   Moore, Eric L ^d   Katz, Ryan D ^d   Shipman, Jennifer M ^d   Garcia Calvo, Margarita ^d   Sharma, Sujata ^d   Sheth, Payal ^d   Soisson, Stephen M ^d   Stevens, Raymond C ^a   Katritch, Vsevolod ^a   Cherezov, Vadim ^a   more..

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c SLAC NATIONAL ACCELERATOR LABORATORY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e DESY   (Germany)

^f UNIVERSITY OF HAMBURG   (Germany)

^g ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; BETA ARRESTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; PROTEIN BINDING;

CRYSTAL STRUCTURE; DESIGN METHOD; GENETIC ANALYSIS; LIGAND; MUTATION;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; GENETIC VARIATION; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MUTAGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; AGONISTS; BINDING SITE; CHEMISTRY; DRUG DESIGN; ENZYME SPECIFICITY; GENETICS; METABOLISM; MOLECULAR MODEL; MUTATION; X RAY CRYSTALLOGRAPHY;

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; BETA-ARRESTINS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 85017413904     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22035     Document Type: Article

References (49)

1. Karnik, S. S. et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli. Pharmacol. Rev. 67, 754-819 (2015).
2. de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W. & Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472 (2000).
3. Zaman, M. A., Oparil, S. & Calhoun, D. A. Drugs targeting the renin-angiotensinaldosterone system. Nat. Rev. Drug Discov. 1, 621-636 (2002).
4. Porrello, E. R., Delbridge, L. M. & Thomas, W. G. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front. Biosci. 14, 958-972 (2009).
5. Guimond, M. O. & Gallo-Payet, N. How does angiotensin AT2 receptor activation help neuronal differentiation and improve neuronal pathological situations? Front. Endocrinol. 3, 164 (2012).
6. Berk, B. C. Angiotensin type 2 receptor (AT2R): a challenging twin. Sci. STKE 2003, pe16 (2003).
7. Miura, S., Matsuo, Y., Kiya, Y., Karnik, S. S. & Saku, K. Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochem. Biophys. Res. Commun. 391, 85-90 (2010).
8. Hein, L., Barsh, G. S., Pratt, R. E., Dzau, V. J. & Kobilka, B. K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 377, 744-747 (1995).
9. Ichiki, T. et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377, 748-750 (1995).
10. Porrello, E. R. et al. Angiotensin II type 2 receptor antagonizes angiotensin II type 1 receptor-mediated cardiomyocyte autophagy. Hypertension 53, 1032-1040 (2009).
11. Ruiz-Ortega, M. et al. Angiotensin II activates nuclear transcription factor kappaB through AT1 and AT2 in vascular smooth muscle cells: molecular mechanisms. Circ. Res. 86, 1266-1272 (2000).
12. Ruiz-Ortega, M., Lorenzo, O., Rupérez, M., Blanco, J. & Egido, J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT1 and AT2 receptors. Am. J. Pathol. 158, 1743-1756 (2001).
13. Caballero, R. et al. Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current. Cardiovasc. Res. 62, 86-95 (2004).
14. Zhao, Y. et al. Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. J. Neurochem. 94, 1395-1401 (2005).
15. Guimond, M. O. & Gallo-Payet, N. The angiotensin II type 2 receptor in brain functions: an update. Int. J. Hypertens. 2012, 351758 (2012).
16. Anand, U. et al. Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur. J. Pain 17, 1012-1026 (2013).
17. Smith, M. T., Woodruff, T. M., Wyse, B. D., Muralidharan, A. & Walther, T. A small molecule angiotensin II type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Med. 14, 1557-1568 (2013).
18. Smith, M. T., Wyse, B. D. & Edwards, S. R. Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med. 14, 692-705 (2013).
19. Smith, M. T., Lau, T., Wallace, V. C., Wyse, B. D. & Rice, A. S. Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy. Behav. Pharmacol. 25, 137-146 (2014).
20. Rice, A. S. et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 383, 1637-1647 (2014).
21. Wan, Y. et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem. 47, 5995-6008 (2004).
22. Kemp, B. A. et al. AT2 receptor activation induces natriuresis and lowers blood pressure. Circ. Res. 115, 388-399 (2014).
23. Larhed, M., Hallberg, M. & Hallberg, A. Nonpeptide AT2 receptor agonists. Med. Chem. Rev. 51, 69-82 (2016).
24. Zhang, H. et al. Structure of the angiotensin receptor revealed by serial femtosecond crystallography. Cell 161, 833-844 (2015).
25. Zhang, H. et al. Structural basis for ligand recognition and functional selectivity at angiotensin receptor. J. Biol. Chem. 290, 29127-29139 (2015).
26. Glinka, T. W. et al. L-161, 638: a potent AT2 selective quinazolinone angiotensin II binding inhibitor. Bioorg. Med. Chem. Lett. 4, 1479-1484 (1994).
27. de Laszlo, S., Glinka, T., Greenlee, W., Chakravarty, P. & Patchett, A. Disubstituted 6-aminoquinazolinones. US patent 5, 385, 894 (1995).
28. Dosa, P. I. & Amin, E. A. Tactical approaches to interconverting GPCR agonists and antagonists. J. Med. Chem. 59, 810-840 (2016).
29. Murugaiah, A. M. et al. From the first selective non-peptide AT2 receptor agonist to structurally related antagonists. J. Med. Chem. 55, 2265-2278 (2012).
30. Chun, E. et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967-976 (2012).
31. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nat. Protocols 4, 706-731 (2009).
32. Liu, W. et al. Serial femtosecond crystallography of G protein-coupled receptors. Science 342, 1521-1524 (2013).
33. Liu, W., Ishchenko, A. & Cherezov, V. Preparation of microcrystals in lipidic cubic phase for serial femtosecond crystallography. Nat. Protocols 9, 2123-2134 (2014).
34. Weierstall, U. et al. Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography. Nat. Commun. 5, 3309 (2014).
35. Ballesteros, J. A. & Weinstein, H. in Methods in Neurosciences Vol. 25 (ed. Sealfon Stuart, C.) 366-428 (Academic Press, 1995).
36. Katritch, V., Cherezov, V. & Stevens, R. C. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53, 531-556 (2013).
37. Venkatakrishnan, A. J. et al. Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region. Nature 536, 484-487 (2016).
38. Rasmussen, S. G. et al. Crystal structure of the β 2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
39. Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615-619 (2013).
40. Katritch, V. et al. Analysis of full and partial agonists binding to β 2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. J. Mol. Recognit. 22, 307-318 (2009).
41. Kang, Y. et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 523, 561-567 (2015).
42. Katritch, V. et al. Allosteric sodium in class A GPCR signaling. Trends Biochem. Sci. 39, 233-244 (2014).
43. Balakumar, P. & Jagadeesh, G. Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor. J. Mol. Endocrinol. 53, R71-R92 (2014).
44. Unal, H. & Karnik, S. S. Constitutive activity in the angiotensin II type 1 receptor: discovery and applications. Adv. Pharmacol. 70, 155-174 (2014).
45. Miura, S. & Karnik, S. S. Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J. Hypertens. 17, 397-404 (1999).
46. Miura, S. & Karnik, S. S. Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. EMBO J. 19, 4026-4035 (2000).
47. Akazawa, H., Yano, M., Yabumoto, C., Kudo-Sakamoto, Y. & Komuro, I. Angiotensin II type 1 and type 2 receptor-induced cell signaling. Curr. Pharm. Des. 19, 2988-2995 (2013).
48. Hein, L., Meinel, L., Pratt, R. E., Dzau, V. J. & Kobilka, B. K. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol. Endocrinol. 11, 1266-1277 (1997).
49. Widdop, R. E., Matrougui, K., Levy, B. I. & Henrion, D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 40, 516-520 (2002). 294-295